Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro.
about
Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.Infrared assessment of bone quality: a reviewFluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivopH-activated nanoparticles for controlled topical delivery of farnesol to disrupt oral biofilm virulence.Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats.Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters.Biomimetic Ca-P coatings incorporating bisphosphonates produced on starch-based degradable biomaterials.Modification of Hydroxyapatite with Ion-Selective Complexants: 1-Hydroxyethane-1,1-diphosphonic Acid.An in vitro assay to measure targeted drug delivery to bone mineral.Differences between bisphosphonates in binding affinities for hydroxyapatite.Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo.In-vivo near-infrared optical imaging of growing osteosarcoma cell lesions xenografted in mice: dual-channel quantitative evaluation of volume and mineralization.Prolonged osteogenesis from human mesenchymal stem cells implanted in immunodeficient mice by using coralline hydroxyapatite incorporating rhBMP2 microspheres.Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
P2860
Q33665130-2638A412-C953-4E4A-86DB-C306569FA75CQ34009569-A0EDE78D-359B-4A49-88A4-EEB03B97A651Q35078785-28A4BEF3-CDED-4872-B93B-2A3F47228267Q35156294-5AFBB671-2BBE-4739-9BF2-191C7297BB96Q35394505-310EC7B8-94F5-4A9D-9149-1AA3B6789484Q36553571-0DE73AC9-4E21-4908-81F5-35FE69FBB042Q39550317-4624BFAB-AA7E-41E5-8263-F88BC8369197Q39809207-2FE4517F-9FBE-4B01-A021-FC6D1FC8A752Q41855681-9D3D845D-AB03-491A-BA56-5A9BF92CFDBEQ43139881-F5ED32D0-0C81-4285-BA39-5ACA6B6B686BQ43244562-6B329B55-2335-4DE1-B1E5-BBF5AC173505Q46284190-7E152F4A-5855-4AB3-8857-ECB7A5B3A63CQ46291900-D6F90594-757D-438B-877E-4BB5958C64BBQ46292642-7563F508-871C-42E9-BB33-8AA5C1D965D4Q51750382-D21ACA2F-3402-4D96-BA5C-6D53433BB596Q51873934-E20CBFF8-287B-46B1-AA2B-50E8209A50AA
P2860
Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bisphosphonate binding affinit ...... apatite dissolution in vitro.
@en
Bisphosphonate binding affinit ...... apatite dissolution in vitro.
@nl
type
label
Bisphosphonate binding affinit ...... apatite dissolution in vitro.
@en
Bisphosphonate binding affinit ...... apatite dissolution in vitro.
@nl
prefLabel
Bisphosphonate binding affinit ...... apatite dissolution in vitro.
@en
Bisphosphonate binding affinit ...... apatite dissolution in vitro.
@nl
P2093
P2860
P356
P1476
Bisphosphonate binding affinit ...... apatite dissolution in vitro.
@en
P2093
F Hal Ebetino
George H Nancollas
R Graham G Russell
Roger J Phipps
Zachary J Henneman
P2860
P304
P356
10.1002/JBM.A.31599
P577
2008-06-01T00:00:00Z